Live Chat
Today's Hours: 12:00pm - 6:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    edited by William R. Jacobs, Jr., Department of Immunology and Microbiology, ... Show More Albert Einstein School of Medicine, Bronx, New York Helen McShane, Cellular Immunology and Vaccine Development Group, Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, United Kingdom, Valerie Mizrahi, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Faculty of Health Sciences, Rondebosch, South Africa, Ian M. Orme, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado.
    Contents:
    Towards Edward Jenner's revenge: developing an effective tuberculosis vaccine
    Drug discovery and development: state of the art and future directions
    Biomarkers and diagnostics
    Host and strain diversity
    The signature problem of tuberculosis persistence.
    Digital Access Wiley 2017
  • Article
    Million R.
    J Int Med Res. 1977;5 Suppl 2:77-80.
    A double-blind crossover trial compared Butacote, 200 mg b.d. with naproxen, 250 mg b.d., each given for four weeks, in the treatment of rheumatoid arthritis. The trial was multicentre, and twenty-six general practitioners admitted forty-eight patients. Seven patients dropped out: two for technical reasons; one in each treatment group because of exacerbation of symptoms; one because of intolerance of rescue analgesic; and two with gastric intolerance to naproxen. Both drugs were effective in relieving pain, morning stiffness, and joint tenderness, as compared with the condition before the trial. There was little effect on grip strength or joint size, and no real differences between the two drugs. The two preparations had a similar frequency and spectrum of side-effects, except that oedema did not occur with naproxen, and rash did not occur with Butacote. Gastro-intestinal upsets were the commonest unwanted effect but only two patients had to stop treatment for this reason, both while taking naproxen. Although the doctors preferred each drug on an equal number of occasions, the patients preferred Butacote to naproxen almost twice as often (20:11), particularly when Butacote was given after naproxen. The reason for this divergence of opinions is not obvious.
    Digital Access Access Options